A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.

Summary

Purpose: To evaluate the effectiveness of intralesional triamcinolone for the treatment of hidradenitis suppurativa (HS) Participants: Patients diagnosed with Hidradenitis Suppurativa that have active inflammatory HS lesions. Up to 60 lesions will be treated. Between 20 and 60 patients will be enrolled dependent on the number of lesions they have treated. (up to 3 per patient) Procedures (methods): Injection of triamcinolone or placebo into active lesions of hidradenitis suppurativa

Timeline

Start

2016-06

Primary completion

2017-06

Completion

2017-07

Outcome

Missed primary endpoint

registry analysis (superiority test); Triamcinolone Acetonide 10mg/mL vs Normal Saline Placebo; p = 0.77; Mixed Models Analysis NCT02781818 ↗

registry analysis (superiority test); Triamcinolone Acetonide 40mg/mL vs Normal Saline Placebo; p = 0.46; Mixed Models Analysis NCT02781818 ↗

Publications

• Fajgenbaum K, Crouse L, Dong L, Zeng D, Sayed C. Intralesional Triamcinolone May Not Be Beneficial for Treating Acute Hidradenitis Suppurativa Lesions: A Double-Blind, Randomized, Placebo-Controlled Trial. Dermatol Surg. 2020 May;46(5):685-689. doi: 10.1097/DSS.0000000000002112.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Triamcinolone Acetonide	Other / unclassified	10 mg/ml	Other
Subject	Triamcinolone Acetonide	Other / unclassified	40 mg/ml	Other

Indications